Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06647979

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material…

United States10 participantsStarted 2025-12-01

Treatment: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452

All recent trials (4 shown)

Not Yet RecruitingNot Applicable

NCT06743113

Hypoxic Red Blood Cells in Sickle Cell Anemia

The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system…

United States48 participantsStarted 2026-03

Treatment: Hemanext ONE System, Conventional RBCs

Not Yet RecruitingPhase 2

NCT07175051

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administra…

United States20 participantsStarted 2025-12

Treatment: Empagliflozin (oral)

Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

All recent trials (4 shown)

Hypoxic Red Blood Cells in Sickle Cell Anemia

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

All recent trials (4 shown)

Hypoxic Red Blood Cells in Sickle Cell Anemia

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia